Zhimeng Biopharma’s investigational drug approved to begin phase 2 epilepsy clinical trial in China

This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis

Briefs: Alembic Pharmaceuticals and Tyche Industries

Alembic receives EIR from USFDA for facility at Panelav

Shukra Pharmaceuticals inks distribution tie-up with Wockhardt

The products include high-quality, advanced anti-infective formulations such as EMROK (Levonadifloxacin) and MIQNAF (Nafithromycin)

NATCO Pharma updates on acquisition of Adcock Ingram

Briefs: Torrent Pharmaceuticals and Hemant Surgical Industries

Hemant Surgical Industries receives order

FDA prohibits Sun Pharma's Halol Plant from exporting drugs to US

Sun Pharma's Halol plant gets OAI classification from US FDA inspection

Mankind Pharma gets CDSCO nod to begin Phase 1 trials of novel Autoimmune drug candidate MKP11093

MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile

Aptar Pharma partners with Dianosic to advance ARIS platform for treatment of chronic allergic rhinitis and rhinosinusitis

Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods

Argo Biopharma inks $5.2 billion deal with Novartis for novel molecules for cardiovascular diseases

Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity

Jagsonpal Pharmaceuticals appoints Amrut Medhekar as Chief Operating Officer